Neriman Sila Koc
Overview
Explore the profile of Neriman Sila Koc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yazdali Koylu N, Koc N, Sancar E, Sarinc S, Altun B
Exp Clin Transplant
. 2024 Jul;
22(6):471-474.
PMID: 39072520
Everolimus is an orally administered mechanistic target of rapamycin inhibitor in solid-organ transplant patients. In addition to the common adverse side effects of this treatment, such as hyperlipidemia, rash, stomatitis,...
2.
Koc N, Yeter H, Yildirim T, Erdem Y, Yilmaz R
Ther Apher Dial
. 2024 Apr;
28(4):591-598.
PMID: 38572624
Introduction: Patients on hemodialysis, especially with diabetes, face elevated cardiovascular events. A major contributor to complications associated with diabetes is advanced glycation end products (AGEs). Removing these compounds is challenging...
3.
Koc N, Yildirim T, Saglam A, Arici M, Erdem Y
Nefrologia (Engl Ed)
. 2022 Sep;
41(4):471-473.
PMID: 36165118
No abstract available.
4.
Oto O, Ozturk S, Arici M, Velioglu A, Dursun B, Guller N, et al.
Clin Kidney J
. 2022 May;
15(5):999-1006.
PMID: 35498893
Background: In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method: The primary endpoint was death...
5.
Koc N, Yildirim T, Girgin S, Onal C, Tahillioglu Y, Yilmaz R, et al.
Ther Apher Dial
. 2022 Feb;
26(6):1182-1186.
PMID: 35199958
Introduction: We aimed to investigate the effect of a standard hemodialysis prescription in hyponatremic patients requiring hemodialysis on the development of osmotic demyelination syndrome. Methods: Ninety-nine patients who were treated...
6.
Yildirim T, Gok-Oguz E, Koc N, Uzerk-Kibar M, Uner M, Saglam E, et al.
Nephron
. 2021 Dec;
146(2):172-178.
PMID: 34852341
Introduction: Patients with AA amyloidosis may present with acute kidney injury that progresses to end-stage kidney disease in a short period of time. Acute allergic tubulointerstitial nephritis (aTIN) is a...
7.
8.
Koc N, Yildirim T, Saglam A, Arici M, Erdem Y
Nefrologia
. 2021 Oct;
41(4):471-473.
PMID: 34629594
No abstract available.
9.
Sekmek S, Yildirim T, Koc N, Onal C, Jabrayilov J, Yilmaz R, et al.
Transplant Proc
. 2021 Jul;
53(6):1951-1956.
PMID: 34274119
Background: Diarrhea is a common adverse effect of mycophenolate treatment in renal transplant recipients. In patients with mycophenolate-induced diarrhea, one option is to switch to mycophenolate to azathioprine. In this...
10.
Yildirim T, Kutahya B, Is F, Erdevir M, Kibar M, Koc N, et al.
Turk J Med Sci
. 2021 May;
51(5):2364-2368.
PMID: 33984890
Background/aim: Compared to healthy controls, mean platelet volume (MPV) is frequently higher in patients with Familial Mediterranean fever (FMF) but lower in AA amyloidosis patients. The reason for the difference...